VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
For more details, the full press release is available at https://ibn.fm/ioEmu.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to prolong patients' lives and improve their quality of life.
This breakthrough is significant because sepsis is a life-threatening condition that requires rapid diagnosis and treatment. Current diagnostic methods often rely on venous blood samples processed in centralized laboratories, which can delay results. The finger-prick prototype could enable testing at the point of care, such as in emergency rooms or even in remote areas, potentially reducing time to treatment and improving patient outcomes.
The ability to detect nucleosomes from a simple finger-prick sample also opens up possibilities for home monitoring and early warning systems for patients at risk of sepsis. Volition's technology could be particularly valuable in low-resource settings where laboratory infrastructure is limited, addressing a critical global health need.
The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit Volition's website at www.Volition.com.
